Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 800-804

  Chen, Rong Xin ^a   Xia, Yun Hong ^a   Xue, Tong Chun ^a   Ye, Sheng Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MicroRNA 96; Osteopontin

Indexed keywords

MICRORNA; MICRORNA 96; OLIGONUCLEOTIDE; OSTEOPONTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; METASTASIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE;

EID: 84856243965     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.695     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Tang ZY, Ye SL, Liu YK, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196, 2004.
3. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
4. Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
5. Bandres E, Cubedo E, Agirre X, et al: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29, 2006.
6. Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216, 2009.
7. Ladeiro Y, Couchy G, Balabaud C, et al: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963, 2008. (Pubitemid 351952843)
8. Sato F, Hatano E, Kitamura K, et al: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 6: e16435, 2011.
9. Pineau P, Volinia S, McJunkin K, et al: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 107: 264-269, 2010.
10. Wang Y, Lee AT, Ma JZ, et al: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283: 13205-13215, 2008.
11. Sassen S, Miska EA and Caldas C: MicroRNA: implications for cancer. Virchows Arch 452: 1-10, 2008.
12. Yang L, Belaguli N and Berger DH: MicroRNA and colorectal cancer. World J Surg 33: 638-646, 2009.
13. Lynam-Lennon N, Maher SG and Reynolds JV: The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc 84: 55-71, 2009.
14. Deng S, Calin GA, Croce CM, Coukos G and Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7: 2643-2646, 2008.
15. Li C, Feng Y, Coukos G and Zhang L: Therapeutic microRNA strategies in human cancer. AAPS J 11: 747-757, 2009.
16. Mishra PJ and Merlino G: MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119: 2119-2123, 2009.
17. Rossi JJ: New hope for a microRNA therapy for liver cancer. Cell 137: 990-992, 2009.
18. Wang V and Wu W: MicroRNA-based therapeutics for cancer. Biodrugs 23: 15-23, 2009.
19. + cells increases USF2-mediated cell growth. Mol Cancer Res 6: 1830-1840, 2008.
20. Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.
21. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004. (Pubitemid 38746324)
22. Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26: 6361-6371, 2007. (Pubitemid 47494216)
23. Coppola D, Szabo M, Boulware D, et al: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004. (Pubitemid 38114178)
24. Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.
25. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006. (Pubitemid 43247403)
26. Chen RX, Xia YH, Cui JF, Xue TC and Ye SL: Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol 25: 1435-1442, 2010.
27. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003. (Pubitemid 36460075)
28. Zhao J, Dong L, Lu B, et al: Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 135: 956-968, 2008.
29. Sun BS, Dong QZ, Ye QH, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48: 1834-1842, 2008.
30. Myatt SS, Wang J, Monteiro LJ, et al: Definition of microRNAs that repress expression of the tumor-suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377, 2010.